VOTRIENT® (pazopanib) for Renal Cell Carcinoma - Cancer Therapy Advisor

VOTRIENT® (pazopanib) for Renal Cell Carcinoma

Slideshow

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

  • Slide

This slideshow reviews drug information for VOTRIENT® (pazopanib) for renal cell carcinoma.

Table of Contents

Slide 3: Indication, Dosage, and Administration
Slide 6: Use in Specific Populations
Slide 8: Clinical Pharmacology
Slide 12: Warnings and Precautions
Slide 19: Clinical Safety and Efficacy
Slide 23: Drug Storage and Supply

Next hm-slideshow in Slides